These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 1303595

  • 1. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
    Pertuiset E, Chevret S, Lioté F, Delauche MC, Bardin T, Dryll A, Kuntz D.
    Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
    [Abstract] [Full Text] [Related]

  • 2. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
    Ben Abid H, Meddeb B, Ben Abdallah M, Bel Hadj Ali Z, Hafsia R, Ben Lakhal R, Gouider E, Aissaoui L, Landoulsi I, ben Abdeladhim A, Hafsia A.
    Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374
    [Abstract] [Full Text] [Related]

  • 3. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V, Zemanova M, Minarik J, Bacovsky J, Ordeltova M, Indrak K, Budikova M, Dusek L, Farbiakova V.
    Neoplasma; 2006 Dec; 53(4):277-84. PubMed ID: 16830053
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors and therapeutic results in multiple myeloma.
    Nagai M, Kitahara T, Minato K, Takenaka T, Konda C, Seki S, Shimoyama M.
    Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
    [Abstract] [Full Text] [Related]

  • 5. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF, Fu WJ, Yuan ZG, Wang DX, Chen YB, Hou J.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1655-8. PubMed ID: 17935664
    [Abstract] [Full Text] [Related]

  • 6. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G, Figueroa M G, Lois V V, Cabrera C ME, León R A, García L H, Rojas R H.
    Rev Med Chil; 2008 Jan 05; 136(1):7-12. PubMed ID: 18483648
    [Abstract] [Full Text] [Related]

  • 7. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P, Colantonio D, Collacciani A, Casale R, Natali G.
    Panminerva Med; 1991 Jan 05; 33(2):93-110. PubMed ID: 1923560
    [Abstract] [Full Text] [Related]

  • 8. International staging system for multiple myeloma.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J.
    J Clin Oncol; 2005 May 20; 23(15):3412-20. PubMed ID: 15809451
    [Abstract] [Full Text] [Related]

  • 9. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J.
    Ai Zheng; 2006 Apr 20; 25(4):461-4. PubMed ID: 16613681
    [Abstract] [Full Text] [Related]

  • 10. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr 20; 29(4):217-21. PubMed ID: 18843972
    [Abstract] [Full Text] [Related]

  • 11. [BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].
    Okada K, Oguchi N, Shinohara K, Tamura N, Ishii K, Noguchi Y, Hayashi S, Yamamoto H, Takeichi M, Fujimoto H, Shirota T, Hayashi T.
    Rinsho Ketsueki; 1997 Dec 20; 38(12):1254-62. PubMed ID: 9455144
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
    Pasqualetti P, Collacciani A, Maccarone C, Casale R.
    Biomed Pharmacother; 1996 Dec 20; 50(1):29-35. PubMed ID: 8672729
    [Abstract] [Full Text] [Related]

  • 13. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
    Pasqualetti P, Colantonio D, Casale R, Lorenzetti G, Natali G.
    Recenti Prog Med; 1989 Oct 20; 80(10):543-6. PubMed ID: 2602637
    [Abstract] [Full Text] [Related]

  • 14. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F, Minoia C, Favoino E, Prete M, Dammacco F.
    Blood Cells Mol Dis; 2009 Oct 20; 42(1):71-6. PubMed ID: 18996035
    [Abstract] [Full Text] [Related]

  • 15. Analysis of criteria in staging in multiple myeloma.
    Pennec Y, Mottier D, Youinou P, Asselain B, Miossec P, Le Goff P, Le Prise PY, Le Menn G.
    Haematologia (Budap); 1982 Oct 20; 15(2):221-6. PubMed ID: 7160667
    [Abstract] [Full Text] [Related]

  • 16. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
    Ailawadhi S, Abdelhalim AN, Derby L, Mashtare TL, Miller KC, Wilding GE, Alberico RA, Gottlieb R, Klippenstein DL, Lee K, Chanan-Khan AA.
    Cancer; 2010 Jan 01; 116(1):84-92. PubMed ID: 19862816
    [Abstract] [Full Text] [Related]

  • 17. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
    Pasqualetti P, Colantonio D, Casale R, Di Lauro G, Collacciani A, Festuccia V, Trotta A, Natali G.
    Ann Ital Med Int; 1990 Jan 01; 5(3 Pt 1):195-204. PubMed ID: 2288822
    [Abstract] [Full Text] [Related]

  • 18. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):497-503. PubMed ID: 10482933
    [Abstract] [Full Text] [Related]

  • 19. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
    Franco M, Fuzibet JG, Cassuto JP, Pesce A, Ziegler G, Dujardin P.
    Rev Rhum Mal Osteoartic; 1985 Nov 01; 52(11):619-23. PubMed ID: 3909365
    [Abstract] [Full Text] [Related]

  • 20. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?
    Baur A, Stäbler A, Nagel D, Lamerz R, Bartl R, Hiller E, Wendtner C, Bachner F, Reiser M.
    Cancer; 2002 Sep 15; 95(6):1334-45. PubMed ID: 12216103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.